Article
Biologic Therapy and Novel Molecular Targets of Severe Asthma.
The journal of allergy and clinical immunology. In practice - 1 Jan 2000
Pepper Amber N, Renz Harald, Casale Thomas B, Garn Holger
Abstract excerpt
Treatment options for severe or uncontrolled asthma are increasing, especially pertaining to novel biologic therapies. The 2 primary asthma endotypes, T2 high and T2 low, are defined by the level of type 2 T helper and innate lymphoid cell activity and mediators. Most therapies for severe asthma target T2 high asthma, including the 3 biologics approved for use in the United States and Europe: omalizumb,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.